Kohen's team explored pirfenidone (PFD) for its antifibrotic activity, aiming to reduce scarring around GDDs without the ...

As the only industry-led forum providing biopharma with the insights necessary to make strategic and scientific decisions on their fibrosis pipeline, the 6th Antifibrotic Drug Development Summit ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

announces the filing of a new patent application directed to the use of Thykamine™ as an antifibrotic agent. Backed by in vivo data, the patent application displays the potential effectiveness ...

Backed by in vivo data, the patent application displays the potential effectiveness of thylakoid extracts in treating and slowing the progression of fibrosis, and in down regulating several genes ...